Q2 2026 saw strong sales and profit growth, led by Hi-Tech E&C and robust trading, with operating margin and order backlog both improving. Biologics announced a major acquisition, and the company is expanding in nuclear, SMR, and data centers. Dividend policy focuses on cash payouts from affiliate…
Q2 2026 saw strong sales and profit growth, led by Hi-Tech E&C and robust trading, with record new orders and improved margins. Outlook remains positive, with Hi-Tech and nuclear projects expected to drive further gains, and a clear dividend policy in place.Based on SAMSUNG C&T CORP [028260] Q2 202…
Sales and operating profit grew strongly year-over-year in 2Q26, led by Engineering & Construction, Trading & Investment, and Bio segments. Strategic investments in energy, data centers, and life sciences support future growth, while cash flow and financial ratios remain robust.Original document: S…
